Holen Sie sich die Stockscreener-App
4.34
1.36%
-0.06
Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten
Lobe Sciences Secures $26M for Novel Chronic Cluster Headache Drug Development | LOBEF Stock News - Stock Titan
Biotech to Environmental Services: Windtree's $12M Revenue Play in $85B Waste Management Market - Stock Titan
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan
Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Regeneron Secures Massive $407M Victory: Jury Finds Amgen Guilty of Illegal PCSK9 Drug Bundling Scheme - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | CYCC Stock News - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Exclusive: ANI Pharmaceuticals CEO Reveals Growth Strategy at Major Ophthalmology Conference - Stock Titan
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Petros Pharmaceuticals Targets $38B Self-Care Market with Game-Changing AI Drug Platform - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
NRx Pharmaceuticals Slashes Losses by 33% While Securing $300M+ Potential Deal - Stock Titan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan
Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):